Interview: BioLineRx Pushes Ahead In Pancreatic Cancer
Combo of BL-8040, Keytruda And Chemo Shows Promise
The Israeli group is confident that its CXCR4 antagonist has potential as a platform molecule for a range of cancers at various stages of disease.
You may also be interested in...
Merck & Co.'s Keytruda, BioLineRx's Motixafortide Combine To Good Effect In Pancreatic Cancer
BioLineRx's Phase IIa study of Keytruda/motixafortide/chemo showed improvements in overall and progression-free survival compared with historical data.
Pharma Giants Urge Biotechs To Get In Touch As Early As Possible
Although money is too tight to mention for some biotechs, last year the value of preclinical partnerships actually went up and Switzerland’s big two pharma players are on the lookout for more.
NASDAQ Listing Done, Oculis Eyes Phase III Readouts
Having taken the special purpose acquisition corporation route to list in the US, Switzerland's Oculis is waiting for some vital late-stage data, notably on OCS-01 for diabetic macular edema.